Here, we share several charts that visualise the extent of psychedelics organisations’ lobbying activities at the federal level, at least according to filings. Most recent data: Q2 2025. ∎
Notes: This data is based on lobbying disclosure filings and, as such, provides a lagging and at times incomplete account of lobbying activity. What’s more, it captures only lobbying that takes place at the federal level, meaning state-level efforts are not reflected here. Please also note that filings must only specify the approximate amount spent where it exceeds $5,000. Otherwise, a $0 figure may be reported. ∎
Pα+ delivers the policy intelligence serious stakeholders rely on. Get in-depth coverage of psychedelic policy and regulation—tracking developments from Capitol Hill to state legislatures. With expert analysis and curated insights, Pα+ keeps you informed on the decisions shaping the future of psychedelics. Subscribe today.
Pα+ subscribers receive regular Bulletins, articles, interviews with insiders and quick-take analysis of major stories and developments (e.g., significant trial results, financing rounds, policy reforms, etc.); along with access to our back catalogue and Library.
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond
Insights and interviews delivered to your inbox. No spam, just valuable information.
